Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe
Author:
Affiliation:
1. Global medical affairs, Takeda Pharmaceuticals AG, Zürich, Switzerland
2. R&D, Alnylam Pharmaceuticals, Paris, France
Funder
funded
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1963435
Reference96 articles.
1. Gassmann O, Schuhmacher A, von ZM, et al. Leading Pharmaceutical Innovation: How to Win the Life Science Race. 3rd ed. 2018, Springer International Publishing : Imprint: Springer, Cham, Germany. 2018.
2. Biosimilars in dermatology
3. Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases
4. Top drugs and companies by sales in 2017
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-11-23
2. Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-10
3. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn’s disease;Biomedicine & Pharmacotherapy;2023-03
4. Biosimilars approved for psoriasis treatment in Europe;PONS - medicinski casopis;2023
5. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry;RMD Open;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3